Sex-Specific Cerebrovascular Dysfunction in Metabolic Syndrome-Role of COX

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 31, 2026

Primary Completion Date

July 31, 2031

Study Completion Date

July 31, 2031

Conditions
Metabolic Syndrome
Interventions
DRUG

Indomethacin

"Indomethacin is a nonsteroidal anti-inflammatory. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation.~Indomethacin (1.5 mg/kg) will be taken orally prior to one MRI study visit."

DRUG

Placebo

Participants will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit.

DIAGNOSTIC_TEST

MRI

CBF testing will be performed on 3T MRI scanners (GE Healthcare)

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT07218653 - Sex-Specific Cerebrovascular Dysfunction in Metabolic Syndrome-Role of COX | Biotech Hunter | Biotech Hunter